Esperion Therapeutics Inc (NAS:ESPR)
$ 2.08 -0.03 (-1.41%) Market Cap: 394.08 Mil Enterprise Value: 445.93 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Esperion Therapeutics Inc at JMP Securities Life Sciences Virtual Conference Transcript

Jun 16, 2021 / 04:00PM GMT
Release Date Price: $24.88 (+0.32%)
Roy Buchanan
JMP Securities LLC - Analyst

Okay, great. Well, thanks to everybody for joining us for the JMP Securities Life Science Conference. My name is Roy Buchanan, I'm in the biotech research side on Jason Butler's team. And next company we have is Esperion Therapeutics. We rated it a Market Outperform. They are developing and commercializing its novel product for lipid management, bempedoic acid. And we're happy to have Sheldon Koenig with us today; he's President and CEO. He has been in the CEO seat -- I think it will be a month tomorrow after joining the Company as Chief Operating Officer at the end of last year.

So thanks for joining us for the fireside today, Sheldon. You've got a very deep experience in the lipid management space at multiple large companies. So maybe just briefly give us your background and talk about that experience.

Sheldon Koenig
Esperion Therapeutics, Inc. - President & CEO

Great, will do. Well, first of all, Roy, thank you so much. And on behalf of Esperion Therapeutics and myself, it's a pleasure to be here

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot